DK2207787T3 - Immunostimulatory oligoribonukleotidanaloger containing modified oligofosfatenheder - Google Patents

Immunostimulatory oligoribonukleotidanaloger containing modified oligofosfatenheder Download PDF

Info

Publication number
DK2207787T3
DK2207787T3 DK08847550.4T DK08847550T DK2207787T3 DK 2207787 T3 DK2207787 T3 DK 2207787T3 DK 08847550 T DK08847550 T DK 08847550T DK 2207787 T3 DK2207787 T3 DK 2207787T3
Authority
DK
Denmark
Prior art keywords
seq
rna
artificial sequence
synthetic oligonucleotide
orn
Prior art date
Application number
DK08847550.4T
Other languages
Danish (da)
English (en)
Inventor
Harald Debelak
Eugen Uhlmann
Original Assignee
Adiutide Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2207787(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adiutide Pharmaceuticals Gmbh filed Critical Adiutide Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK2207787T3 publication Critical patent/DK2207787T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
DK08847550.4T 2007-11-06 2008-10-30 Immunostimulatory oligoribonukleotidanaloger containing modified oligofosfatenheder DK2207787T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US204907P 2007-11-06 2007-11-06
PCT/IB2008/002940 WO2009060281A2 (en) 2007-11-06 2008-10-30 Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties

Publications (1)

Publication Number Publication Date
DK2207787T3 true DK2207787T3 (en) 2015-02-09

Family

ID=40626260

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08847550.4T DK2207787T3 (en) 2007-11-06 2008-10-30 Immunostimulatory oligoribonukleotidanaloger containing modified oligofosfatenheder

Country Status (10)

Country Link
US (2) US8349812B2 (https=)
EP (1) EP2207787B1 (https=)
JP (1) JP5753382B2 (https=)
AU (1) AU2008326187B2 (https=)
CA (1) CA2704853C (https=)
DK (1) DK2207787T3 (https=)
ES (1) ES2530215T3 (https=)
HR (1) HRP20150131T1 (https=)
PT (1) PT2207787E (https=)
WO (1) WO2009060281A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
CN101820908A (zh) * 2007-10-09 2010-09-01 科利制药公司 包含改性糖部分的免疫刺激寡核苷酸类似物
WO2009141146A1 (en) * 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2012079115A1 (en) * 2010-12-14 2012-06-21 Commonwealth Scientific And Industrial Research Organisation Immunostimulatory oligonucleotides
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US20140287023A1 (en) * 2013-02-11 2014-09-25 Mcgill University 5'-triphosphate oligoribonucleotides
WO2014169049A1 (en) 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
EP3362563A1 (en) 2015-10-14 2018-08-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for liposomal formulation
JP7132911B2 (ja) 2016-09-16 2022-09-07 バイオ－パス ホールディングス， インコーポレイテッド リポソームアンチセンスオリゴヌクレオチドとの併用療法
US11382966B2 (en) 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
CN110709515A (zh) 2017-04-03 2020-01-17 杜克大学 用于差异性诱导细胞死亡和干扰素表达的组合物和方法
IL269608B2 (en) * 2017-04-19 2024-06-01 Bio Path Holdings Inc Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease
EP3612160A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION
EP3990635A1 (en) 2019-06-27 2022-05-04 Rigontec GmbH Design method for optimized rig-i ligands
KR20230013266A (ko) * 2020-05-19 2023-01-26 허드슨 인스티튜트 오브 메디컬 리서치 올리고뉴클레오티드
AU2024321134A1 (en) * 2023-08-10 2026-02-19 Harness Therapeutics Limited Functional nucleic acid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534017A (en) 1967-03-14 1970-10-13 Kyowa Hakko Kogyo Kk Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates
FR1566530A (https=) 1967-03-14 1969-05-09
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
DE19935303A1 (de) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6268790B1 (en) 2000-03-24 2001-07-31 Trw Inc. Anti-theft method and apparatus
WO2003008432A1 (en) 2001-07-16 2003-01-30 Isis Pharmaceuticals, Inc. Process for the preparation of alpha modified nucleoside triphosphates and compounds therefrom
WO2003072757A2 (en) 2002-02-28 2003-09-04 Biota, Inc. Nucleotide mimics and their prodrugs
EP3006043B1 (en) * 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
EP1819364A4 (en) * 2004-12-08 2010-12-29 3M Innovative Properties Co COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
US20060178334A1 (en) 2005-02-04 2006-08-10 City Of Hope Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
EP1924284A1 (en) 2005-09-14 2008-05-28 Hartmann, Gunther Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
WO2007038720A2 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
KR20080065656A (ko) * 2005-10-12 2008-07-14 캔써 리서치 테크놀로지 리미티드 면역질환을 치료하기 위한 방법 및 조성물
DK2405002T3 (en) * 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonukleotidformuleringer
KR101221589B1 (ko) * 2006-04-07 2013-01-15 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물
EP1920775B1 (en) 2006-10-10 2012-12-19 Gunther Prof. Dr. Hartmann 5'Triphosphate oligonucleotide induces anti-viral response

Also Published As

Publication number Publication date
PT2207787E (pt) 2015-02-17
JP5753382B2 (ja) 2015-07-22
CA2704853A1 (en) 2009-05-14
EP2207787A2 (en) 2010-07-21
JP2011502979A (ja) 2011-01-27
WO2009060281A3 (en) 2009-08-13
CA2704853C (en) 2017-08-15
EP2207787B1 (en) 2014-11-12
US20100260788A1 (en) 2010-10-14
HRP20150131T1 (hr) 2015-04-10
ES2530215T3 (es) 2015-02-27
US9156875B2 (en) 2015-10-13
AU2008326187B2 (en) 2014-12-04
US20130164333A1 (en) 2013-06-27
WO2009060281A2 (en) 2009-05-14
AU2008326187A1 (en) 2009-05-14
US8349812B2 (en) 2013-01-08

Similar Documents

Publication Publication Date Title
DK2207787T3 (en) Immunostimulatory oligoribonukleotidanaloger containing modified oligofosfatenheder
AU2003259916B2 (en) Immunostimulatory nucleic acids
US8580268B2 (en) CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
JP2011502979A5 (https=)
AU2008309264B2 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
WO2009030996A1 (en) Triazole compounds as toll-like receptor (tlr) agonists
WO2009030998A1 (en) Pyrimidine compounds as toll-like receptor (tlr) agonists
AU2006241149A1 (en) Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
DK2170353T3 (en) The phosphate-modified oligonucleotide analogs with immunostimulatory activity
HK1154903B (en) Immunostimulatory nucleic acids